TRUC Tregs Suppress Antibody Formation Against Factor VIII
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The formation of anti-drug antibodies (ADAs) interferes with the efficacy of biologics such as protein or enzyme replacement therapy, leading to reduced efficacy and potentially severe adverse reactions, and predicting which patients will develop ADAs is difficult, with limited effective mitigation strategies.
Innovation Solution
Engineered regulatory T cells (TRUC Tregs) that utilize 'TCR-like' signaling by reconfiguring the endogenous TCR-CD3 signaling to respond to scFv-based recognition, suppressing antibody formation against therapeutic agents like factor VIII in hemophilia A patients, without requiring MHC class II restriction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional biologics therapy is administered repeatedly, then therapeutic effect is maintained, but anti-drug antibodies (ADAs) form and neutralize the drug, reducing efficacy
Solution Approach 1:
The patent applies preliminary anti-action by administering engineered Tregs to patients before they receive biologics therapy. These pre-administered Tregs are specifically designed to recognize and suppress the formation of anti-drug antibodies, thereby preventing the neutralization of therapeutic biologics before it can occur. This proactive approach addresses the contradiction by establishing immune suppression mechanisms in advance, allowing repeated biologics administration without ADA-mediated efficacy loss
Solution Approach 2:
The patent uses engineered Tregs as an intermediary between the patient's immune system and the therapeutic biologics. These Tregs express chimeric antigen receptors (CARs) or TCR fusion constructs that enable them to specifically recognize drug-antigen complexes and intervene in the immune response. This intermediary mechanism allows the system to maintain therapeutic efficacy while blocking the harmful ADA formation pathway, resolving the contradiction between maintaining therapy and preventing immune neutralization
2Object-affected harmful factors
If polyclonal Tregs are used for immune suppression, then broad immunosuppressive effect is achieved, but antigen-specific suppression is insufficient due to low precursor frequencies
Solution Approach 1:
The patent applies local quality by engineering Tregs with specific antigen recognition capabilities through CAR or TCR fusion construct expression. This allows the Treg population to have heterogeneous properties: some Tregs are engineered to specifically recognize and suppress responses to particular biologics or antigens, while others maintain broad suppressive functions. This local differentiation of Treg functionality resolves the contradiction by providing both broad immunosuppression and targeted antigen-specific suppression simultaneously
Solution Approach 2:
The patent employs parameter changes by modifying key characteristics of Tregs through genetic engineering. By introducing CARs or TCR fusion constructs, the patent fundamentally changes the antigen recognition parameters of Tregs, transforming them from polyclonal cells with limited specificity to engineered cells with enhanced, defined antigen-specific suppressive capabilities. This parameter modification enables the Tregs to overcome low precursor frequencies and provide robust antigen-specific suppression while maintaining broad immunosuppressive effects
3Measurement precision
If CAR Tregs are engineered with high-affinity scFv, then targeted suppression is improved, but off-target immunosuppression and cytotoxic effects increase
Solution Approach 1:
The patent applies partial or excessive action by using moderate-affinity scFv in CAR design rather than maximizing affinity. This approach provides sufficient targeted suppression of antigen-specific immune responses while avoiding the excessive binding that would lead to off-target effects. By calibrating the affinity to an optimal level rather than maximizing it, the patent resolves the contradiction between achieving adequate targeted suppression and preventing harmful off-target immunosuppression
Solution Approach 2:
The patent employs dynamics by designing CAR Tregs with controllable activation thresholds and regulated suppressive function. The engineered Tregs can dynamically adjust their suppressive activity based on antigen presence and immune context, preventing constitutive off-target suppression while maintaining effective targeted suppression when needed. This dynamic regulation resolves the contradiction by making the suppressive effect conditional rather than constant, allowing targeted action without persistent off-target harm
Data Source
AI summary
Disclosed herein are compositions comprising engineered antigen-specific Tregs that suppress antibody formation against the soluble therapeutic protein factor VIII in an MIC-independent fashion. Complexing TCR-based signaling with single-chain variable fragment (scFv) recognition to generate TCR fusion construct (TRUC)-Tregs delivered controlled antigen-specific signaling via engagement of the entire TCR complex, thereby directing functional suppression of the FVIII-specific antibody response.